| h-var-106f5023b1 | CCL2 Gradient Disruption via Astrocytic CXCL12 Upregulation for CNS Immune Privi | 0.38 | 0.26 | CXCL12 | proposed | 2026-04-27 | SDA-2026-04-16-frontier-immunomics-e6f97b29 |
| h-var-cb5e57de02 | CYP2J2-Derived DHA Epoxides Modulate Microglial M2 Polarization to Reduce Neuroi | 0.38 | 0.34 | CYP2J2/microglial PPAR-γ | proposed | 2026-04-27 | SDA-2026-04-16-frontier-lipidomics-dcdbc360 |
| h-var-b046808f73 | CRP-Mediated CCR2+ Monocyte Recruitment Drives Microglial IL-1β Amplification an | 0.38 | 0.26 | CCR2, TLR4, IL1B | proposed | 2026-04-27 | SDA-2026-04-16-frontier-immunomics-e6f97b29 |
| h-var-b066cde5b5 | Circulating hs-CRP as Disease-Modifying Target via Astrocytic NLRP3 Inflammasome | 0.38 | 0.26 | CRP → NLRP3 → IL-1β/IL-18 | proposed | 2026-04-27 | SDA-2026-04-16-frontier-immunomics-e6f97b29 |
| h-var-f765378ad3 | Lentiviral-Mediated Astrocytic IGFBPL1 Expression via GFAP Promoter | 0.38 | 0.26 | IGFBPL1 | proposed | 2026-04-27 | SDA-2026-04-06-gap-debate-20260406-062045-6addd0cf |
| h-var-99baab6d43 | FUS-Enhanced AAV-PHP.eB Delivery for Microglial IGFBPL1 Expression | 0.38 | 0.26 | IGFBPL1 | proposed | 2026-04-27 | SDA-2026-04-06-gap-debate-20260406-062045-6addd0cf |
| h-var-66f8d10cd1 | Ultrasound-Responsive Liposomal Nanocarriers with Thermosensitive Release | 0.38 | 0.26 | IGFBPL1 | proposed | 2026-04-27 | SDA-2026-04-06-gap-debate-20260406-062045-6addd0cf |
| h-var-d865aeb1ca | Microglial Phenotypic Polarization via CSF1R-Mediated Metabolic Reprogramming | 0.38 | 0.38 | CSF1R | proposed | 2026-04-27 | SDA-2026-04-07-gap-debate-20260406-062045-56983337 |
| h-var-d0bf0fed1b | CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metabolic Reprogramming i | 0.38 | 0.34 | CCR2 | proposed | 2026-04-27 | SDA-2026-04-07-gap-debate-20260406-062045-56983337 |
| h-var-5fc1767ef7 | Astrocytic Metabolic Trained Immunity via AMPK-PGC1α Axis | 0.38 | 0.34 | PRKAA1/PPARGC1A | proposed | 2026-04-27 | SDA-2026-04-07-gap-debate-20260406-062045-56983337 |
| h-var-2a13bbdf73 | Microglia-Mediated Synaptic Pruning Modulation to Optimize Functional Connectome | 0.38 | 0.26 | CX3CR1 | proposed | 2026-04-27 | SDA-2026-04-16-frontier-connectomics-84acb35a |
| h-var-d171eed9a7 | TREM2-Mediated Microglial Regulation of Oligodendrocyte Precursor Cell Recruitme | 0.38 | 0.34 | TREM2 | proposed | 2026-04-27 | SDA-2026-04-16-frontier-connectomics-84acb35a |
| h-var-45de48a8ff | Astrocytic TREM2-Like Receptor Modulation of Synaptic Strengthening Pathways | 0.38 | 0.34 | TREML2 | proposed | 2026-04-27 | SDA-2026-04-16-frontier-connectomics-84acb35a |
| h-var-4ae5ef95fa | Plasma TREM2 Ectodomain Glycosylation Patterns as Microglial Senescence Biomarke | 0.38 | 0.27 | TREM2/ST6GAL1/MGAT5 | proposed | 2026-04-27 | SDA-2026-04-06-gap-debate-20260406-062039-3b945972 |
| h-var-03da47e875 | CSF TREM2 Fragment Ratio Integrated with Neuroinflammatory Cascade Markers | 0.38 | 0.35 | TREM2 | proposed | 2026-04-27 | SDA-2026-04-06-gap-debate-20260406-062039-3b945972 |
| h-var-92ba62855a | Dynamic Blood-Based Exosome Panel for Real-Time Neuroinflammatory State Monitori | 0.38 | 0.35 | CHI3L1/TREM2/NRGN | proposed | 2026-04-27 | SDA-2026-04-06-gap-debate-20260406-062039-3b945972 |
| h-var-7586582905 | Optogenetic restoration of SST interneuron-mediated dendritic inhibition to resc | 0.38 | 0.67 | SST | promoted | 2026-04-27 | SDA-2026-04-03-26abc5e5f9f2 |
| h-var-9c631a92e3 | Closed-loop transcranial focused ultrasound with adaptive API-guided targeting t | 0.38 | 0.18 | PVALB | archived | 2026-04-27 | SDA-BIOMNI-SURVIVAL-3e217f4d |
| h-var-f19c7ae9e4 | Mitochondrial Dysfunction-Mediated Neurodegeneration in Alzheimer's Disease | 0.38 | 0.22 | TFAM | archived | 2026-04-27 | SDA-BIOMNI-SURVIVAL-3e217f4d |
| h-db6058d23e | Glucosylceramide-mediated feedback loop drives GBA-synuclein pathology | 0.38 | 0.72 | GBA1 | proposed | 2026-04-27 | gba-pd |
| h-f210a4000e | Gut butyrate deficiency impairs microglial amyloid clearance via HDAC2-mediated | 0.38 | 0.68 | HDAC2 | proposed | 2026-04-27 | gut-brain-ad |
| h-ae2e26d8a3 | APOE4-driven loss of neuronal PI(4,5)P2 bridges ganglioside-mediated amyloid nuc | 0.38 | 0.72 | APOE | proposed | 2026-04-27 | SDA-2026-04-04-frontier-lipidomics-dcdbc360 |
| h-29e62b7a81 | Gut dysbiosis-driven monocyte reprogramming toward NETotic phenotype accelerates | 0.38 | 0.72 | MMP9 | proposed | 2026-04-27 | SDA-2026-04-04-frontier-immunomics-e6f97b29 |
| h-a8d0be776e | Astrocyte CD38-erk Mapk signaling controls mitochondrial transfer to neurons via | 0.38 | 0.72 | CD38 | proposed | 2026-04-27 | sda-2026-04-01-gap-20260401231108 |
| h-4bc00f3610 | Thalamic anterior nucleus hyperconnectivity drives early-stage functional compen | 0.38 | 0.68 | ENTPD1 | proposed | 2026-04-27 | SDA-2026-04-04-frontier-connectomics-84acb35a |
| h-var-b552a96894 | Chaperone-Autophagy Coupling Prevents Aggregate Persistence by Shunting Seeds to | 0.38 | 0.34 | SQSTM1 (p62) | proposed | 2026-04-27 | SDA-2026-04-06-gap-debate-20260406-062052-28cbc764 |
| h-var-9031067037 | Kinetic Threshold Model Predicts CHIP-Mediated Clearance Requirements for Preven | 0.38 | 0.33 | STUB1 | proposed | 2026-04-27 | SDA-2026-04-06-gap-debate-20260406-062052-28cbc764 |
| h-var-d636c381a4 | Lysosomal Clearance Capacity Determines Therapeutic Window—Autophagy Enhancement | 0.38 | 0.33 | ULK1 (autophagy initiation kinase) | proposed | 2026-04-27 | SDA-2026-04-06-gap-debate-20260406-062052-28cbc764 |
| h-var-82928adf4e | J-protein co-chaperone repertoire drives ATP-independent disaggregation through | 0.38 | 0.37 | DNAJB6, DNAJB2, HSPA8, HSPA1A | proposed | 2026-04-27 | SDA-2026-04-10-gap-debate-20260410-075012-32bac138 |
| h-var-10237959a6 | Dopaminergic Ventral Tegmental-Striatal Circuit Protection | 0.38 | 0.62 | MAPT | promoted | 2026-04-27 | SDA-2026-04-03-26abc5e5f9f2 |
| h-var-470ed722ad | SULF-Mediated Protection of Cholinergic Tau Transport Pathways | 0.38 | 0.33 | SULF1/SULF2 | proposed | 2026-04-27 | SDA-2026-04-04-gap-tau-prion-spreading |
| h-var-6bba3e5e9a | Enhancing Heparan Sulfate 3-O-Sulfotransferase Activity to Competitively Block T | 0.38 | 0.33 | HS3ST3A1/HS3ST3B1 | proposed | 2026-04-27 | SDA-2026-04-04-gap-tau-prion-spreading |
| h-var-75d9ff29fc | TBK1 Inhibitors as ALS Therapeutics: Targeting Downstream STING Signaling | 0.38 | 0.33 | TBK1 | proposed | 2026-04-27 | SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018 |
| h-var-83a78c2c20 | STING-Mediated NLRP3 Inflammasome Priming in ALS Microglia | 0.38 | 0.55 | TMEM173 | promoted | 2026-04-27 | SDA-2026-04-03-gap-immune-atlas-neuroinflam-20260402 |
| h-var-9aaee4c214 | NLRP3/Autophagy Flux Enhancement in Astrocytes | 0.38 | 0.55 | TFEB | promoted | 2026-04-27 | SDA-2026-04-03-gap-immune-atlas-neuroinflam-20260402 |
| h-var-24303a8194 | Transcranial Magnetic Stimulation-Induced Nanoparticle Delivery via Neuronal Act | 0.38 | 0.34 | CACNA1C/SCN9A neuronal channels; CLDN5/ZO-1 | proposed | 2026-04-27 | SDA-2026-04-02-gap-bbb-antibody-transport |
| h-var-d1632ebb0f | Focused Ultrasound-Enhanced CYP46A1 Gene Therapy for Neurodegeneration | 0.38 | 0.61 | CYP46A1 | promoted | 2026-04-27 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| h-var-42910c6bed | CYP46A1 Inhibition Therapy for Neurodegeneration | 0.38 | 0.61 | CYP46A1 | promoted | 2026-04-27 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| h-var-80aad0dc7c | Theta-Gamma Cross-Frequency Coupling Modulates lncRNA-9969 Phase-Dependent Trans | 0.38 | 0.26 | SST, FMRP, lncRNA-9969, ULK1 | proposed | 2026-04-27 | SDA-2026-04-16-gap-pubmed-20260410-150509-76c40dac |
| h-var-074f135782 | CREB1-Induced lncRNA-9969 Selectively Sequesters miR-6361 Through Dual Seed-Stru | 0.38 | 0.34 | lncRNA-9969, CREB1, PVALB | proposed | 2026-04-27 | SDA-2026-04-26-gap-pubmed-20260410-150509-76c40dac-debate |
| h-var-829523e5d2 | Competitive endogenous RNA mechanism enables lncRNA-0021 to modulate mmu-miR-636 | 0.38 | 0.34 | lncRNA-0021 | proposed | 2026-04-27 | SDA-2026-04-26-gap-pubmed-20260410-150509-76c40dac-debate |
| h-var-c4819cffc2 | Mitochondrial DNA Release-STING Axis as Senolytic Efficacy Predictor | 0.38 | 0.38 | CGAS, STING1, MT-DNA | proposed | 2026-04-27 | SDA-2026-04-07-gap-debate-20260406-062101-724971bc |
| h-var-3edf3a7706 | miR-33 Antisense-Enhanced APOE4 Lipidation as Senolytic Timing Biomarker | 0.38 | 0.29 | miR-33, ABCA1, CDKN2A, CGAS | promoted | 2026-04-27 | SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e |
| h-var-9662d2e636 | SREBF2 Direct Activator Hyper-Lipidation Strategy | 0.38 | 0.29 | SREBF2/ABCA1 | promoted | 2026-04-27 | SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e |
| h-var-7b45fa04f3 | Enhancement of Astrocytic Ketone Body Production via HMGCS2 Overexpression | 0.38 | 0.26 | HMGCS2 | proposed | 2026-04-27 | SDA-2026-04-16-frontier-metabolomics-f03b09d9 |
| h-var-cbd9922117 | NAD+-Dependent Transcriptional Upregulation of MCT1 to Restore Neuronal Ketone M | 0.38 | 0.26 | SLC16A1 (MCT1) | proposed | 2026-04-27 | SDA-2026-04-16-frontier-metabolomics-f03b09d9 |
| h-var-f40275ceb0 | CD38 Inhibition to Prevent NAD+ Depletion and Restore Cellular Bioenergetics in | 0.38 | 0.26 | CD38, SIRT1/3 | proposed | 2026-04-27 | SDA-2026-04-16-frontier-metabolomics-f03b09d9 |
| h-var-5aea9e24d1 | ABCA1 Upregulation via LXRβ Agonism to Enhance Cholesterol Efflux and Prevent Ne | 0.38 | 0.34 | ABCA1 | proposed | 2026-04-27 | SDA-2026-04-16-frontier-lipidomics-dcdbc360 |
| h-var-ec13cac789 | CYP2J2-Generated DHA Epoxides Enhance LXRβ-Mediated APOE Lipidation for Synergis | 0.38 | 0.34 | CYP2J2 | proposed | 2026-04-27 | SDA-2026-04-16-frontier-lipidomics-dcdbc360 |
| h-var-135da2778f | ω-3 Docosahexaenoic Acid (DHA) Metabolism via 15-Lipoxygenase to Generate Specia | 0.38 | 0.34 | ALOX15/15-LOX | proposed | 2026-04-27 | SDA-2026-04-16-frontier-lipidomics-dcdbc360 |